NCT00408681 · OUTCOME

Recurrent or Progressive Malignancy

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant · Source last updated 2017-03-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 2 years after enrollment

What was measured

Recurrence or progression of the malignant disease that was the reason for hematopoietic cell transplantation

Groups in this outcome

Treated Patients

Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treated Patients	20

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treated Patients	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1

denoms

counts
group Id
OG000
value
20
units
Participants

description

Recurrence or progression of the malignant disease that was the reason for hematopoietic cell transplantation

groups

description
Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Treated Patients

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

2 years after enrollment

title

Recurrent or Progressive Malignancy

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice